Patent classifications
A61K31/7072
BICYCLIC COMPOUNDS
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
BICYCLIC COMPOUNDS
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells
The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells
The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
Substituted nucleosides, nucleotides and analogs thereof
Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
Substituted nucleosides, nucleotides and analogs thereof
Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
##STR00001##
Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
##STR00001##
Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
STABLE FORMULATIONS FOR THE ORAL ADMINISTRATION OF AMPHOTERICIN B AND RELATED METHODS
The present invention provides oral AmpB and/or protease inhibitor formulations and their use to treat infectious disease, including HIV.
STABLE FORMULATIONS FOR THE ORAL ADMINISTRATION OF AMPHOTERICIN B AND RELATED METHODS
The present invention provides oral AmpB and/or protease inhibitor formulations and their use to treat infectious disease, including HIV.